Lack of current implantable cardioverter defibrillator guidelines application for primary prevention of sudden cardiac death in Latin American patients with heart failure: A cross-sectional study

Europace

Volumn 15, Issue 2, 2013, Pages 236-242

  Gonzalez Zuelgaray, Jorge ^a   Pellizon, Oscar ^b   Muratore, Claudio A ^c   Oropeza, Elsa Silva ^d   Rabinovich, Rafael ^e   Ramos, José Luis ^f   Tentori, Maria Cristina ^c   Reyes, Nicolás ^g   Aguayo, Rubén ^h   Marin, Jorge ⁱ   Peterson, Brett J ^j  

^a Sanatorio de la Trinidad   (Argentina)

^b Hospital Provincial del Centenario   (Argentina)

^c HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e Sanatorio Modelo Quilmes   (Argentina)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^g Section of Geriatrics   (Mexico)

^h HOSPITAL SAN JUAN DE DIOS   (Chile)

ⁱ Clinica Medellin   (Colombia)

^j MEDTRONIC INC   (United States)

more..

Author keywords

Guidelines; Heart failure; Implantable cardiac defibrillators; Sudden cardiac death

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CORONARY CARE UNIT; CROSS-SECTIONAL STUDY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; SUDDEN CARDIAC DEATH; ADOLESCENT; AGED; CARDIOLOGY; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; HEART VENTRICLE TACHYCARDIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RISK FACTOR; STANDARD; STATISTICS; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOLOGY; CHILD; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; LATIN AMERICA; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TACHYCARDIA, VENTRICULAR; YOUNG ADULT;

MLCS; MLOWN;

EID: 84879728359     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eus253     Document Type: Article

References (31)

1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
2. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
3. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
4. Muratore C, Belziti C, Gant Lopez J, Di Toro D, Mulassi A, Corte M et al. Incidencia y variables asociadas con la muerte súbita en una población general. Subanálisis del estudio PRISMA. Rev Argent Cardiol 2006;74:441-6.
5. Mond H, Proclemer A. The 11thWorld Survey of Cardiac Pacing and Implantable Cardioverter-Defibrillators: Calendar Year 2009-A World Society of Arrhythmia's Project. PACE 2011;34:1013-27.
6. Ramos JL, Muratore C, Pachon Mateos JC, Rodriguez A, Gonzalez Hermosillo A, Asenjo R et al. Prevención primaria y secundaria de muerte súbita en el ICD Registry Latin America. Arch Cardiol Mex 2008;78:400-6.
7. Shah B, Hernandez A, Liang L, Al-Khatib S, Yancy C, Fonarow G et al. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure. J Am Coll Cardiol 2009;53:416-22.
8. Fonarow GC, Albert NM, Curtis AB, Gattis W, Gheorghiade M, Tomas Heywood J et al. Improving evidence-based care for heart failure in outpatient cardiology practices: Primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010;122:585-96.
9. Ruskin JN, Camm AJ, Zipes DP, Hallstrom AP, McGrory-Usset ME. Implantable cardioverter defibrillator utilization based on discharge diagnosis from medicare and managed care patients. J Cardiovasc Electrophysiol 2002;13:38-43.
10. Hernandez AF, Fonarow GC, Liang L, Al-Khatib S, Curtis L, LaBresch K et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007;298:1525-32.
11. Voller H, KamkeW, Klein H, Block M, Reibis R, Treusch S et al. Clinical practice of defibrillator implantation after myocardial infarction: Impact of implant time: Results from the PreSCD II Registry. Europace 2011;13:499-508.
12. Plummer Ch, Irving R, McComb J. The incidence of implantable cardioverter defibrillator indications in patients admitted to all coronary care units in a single district. Europace 2005;7:266-72.
13. Huang DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML, Hall WJ et al. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: A MADIT-II substudy. J Cardiovasc Electrophysiol 2007;18:833-8.
14. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study CONSENSUS. N Engl J Med 1987;316:1429-35.
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
16. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr., Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial: The SAVE Investigators. N Engl J Med 1992;327:669-77.
17. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344: 1651-58.
18. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF): MERIT-HF Study Group. JAMA 2000;283:1295302.
19. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341: 709-17.
20. Kawashiro N, Kasanuki H, Ogawa H, Matsuda N, Hagiwara N. Clinical characteristics and outcome of hospitalized patients with congestive heart failure: Results of the HIJC-HF registry. Circ J 2008;72:2015-20.
21. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: Findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007;153:1021-8.
22. Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): A report from the ADHERE registry. Heart Fail Rev 2004;9: 179-85.
23. Echols MR, Felker GM, Thomas KL, Pieper KS, Garg J, Cuffe M et al. Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: Results from the OPTIME-CHF trial. J Card Fail 2006;12:684-8.
24. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-12.
25. Adams KF Jr., Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham W et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16.
26. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C et al. Systematic review: Implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med 2007;147: 251-62.
27. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-80.
28. Alcaraz A, Gonzalez-Zuelgaray J, Augustovski F. Costo-Efectividad del Cardiodesfibrilador Implantable en Pacientes con Factores de Riesgo de Muerte Subita en Argentina. Value Health 2011;14:S33-8.
29. Mark DB, Nelson CL, Anstrom KJ, Al-Khatib S, Tsiatis AA, Cowper PA et al. Costeffectiveness of defibrillator therapy oramiodarone in chronic stable heart failure: Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006;114:135-42.
30. Ribeiro RA, Stella SF, Zimerman L, Pimentel M, Rohde L, Polanczy C. Costeffectiveness of implantable cardioverter-defibrillators in Brazil in the public and private sectors. Arq Bras Cardiol 2010;95:577-86.
31. Tversky A, Kahneman D. Judgement under uncertainty: Heuristics and biases. Science 1974;185:1124-31.